Category: Bayer HealthCareSyndicate content

Report: Bayer explores sale of diabetes device unit

November 25, 2014 by MassDevice

Bayer is reportedly exploring a sale of its diabetes device business, which could fetch as much as $2.5 billion from interested private equity buyers.

Report: Bayer explores sale of diabetes device unit

(Reuters) — Bayer (PINK:BAYRY) is considering the sale of its diabetes device business, Bloomberg reported, citing sources.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Boston Scientific closes $415 Bayer interventions buy

September 2, 2014 by Brad Perriello

Boston Scientific says it's closed the $415 million acquisition of Bayer AG's interventions unit, nearly doubling the size of its peripherals business.

Boston Scientific closes $415 Bayer interventions buy

Boston Scientific (NYSE:BSX) said today that it closed on the $415 million cash buyout of Bayer AG's interventional unit it announced last May.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Boston Scientific's peripherals buy bad news for Cardiovascular Systems? | Medtech Wall Street news for the week of May 19, 2014

May 22, 2014 by MassDevice

Here's a look at some of the top Wall Street stories for medical device companies this week: Is Boston Scientific's peripherals buy bad news for Cardiovascular Systems?; M&A: Medtech makers use acquisitions to fill niches; Report: Deals in the medical device sector rose 200% in Q1; CareFusion plans $1B debt offering; Activist investor Oracle revives proxy war at Biolase.

Is Boston Scientific's peripherals buy bad news for Cardiovascular Systems?

May 15, 2014 by Arezu Sarvestani

Is Boston Scientific's peripherals buy bad news for Cardiovascular Systems?

Is Boston Scientific's peripherals buy bad news for Cardiovascular Systems?

May 15, 2014 by Arezu Sarvestani

Cardiovascular Systems' shares drop as Boston Scientific positions itself as a peripherals market rival with the $415 million acquisition of Bayer AG's interventional business.

Is Boston Scientific's peripherals buy bad news for Cardiovascular Systems?

Boston Scientific's (NYSE:BSX) $415 million acquisition of Bayer AG's interventional unit is a strong move for the company, but it may bode ill for other peripheral players.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Boston Scientific bolsters peripheral business with $415M Bayer buy

May 15, 2014 by Brad Perriello

Boston Scientific agrees to a $415 million deal to add Bayer's interventional business to its peripheral interventions unit, adding thrombectomy and atherectomy devices to its portfolio.

Boston Scientific to acquire Bayer's peripheral busines for $415M

Boston Scientific (NYSE:BSX) said it agreed to acquire Bayer AG's interventional unit for $415 million, in a move to significantly bolster its own $200 million peripheral interventions business.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Anti-Essure movement grows online as women slam Bayer's implant | MassDevice.com On Call

November 13, 2013 by Arezu Sarvestani

Women rallying against the Essure contraceptive implant are congregating online and picketing on street corners, calling on Bayer to recall the device.

MassDevice On Call

MASSDEVICE ON CALL — The anti-Essure movement, launched by women who claim the permanent contraceptive implant left them with severe pain and injuries, doesn't look likely to die down, having spawned Facebook support pages, Twitter campaigns and lots of media attention.

The movement has attached itself to the Twitter hashtag '#EssureRally', through which women are calling on Bayer to recall the device, posting pictures of the ralliers in action and organizing real-world events, including street-corner picketing and conference calls with famed consumer advocate Erin Brockovich.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp